title: Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation.
abstract: BACKGROUND
  Type 2 Diabetes mellitus (T2DM) is a common comorbidity in patients after heart transplantation (HTx) and is associated with adverse long-term outcomes.
  
  
  METHODS
  The retrospective study reported here analyzed the effects of vildagliptin therapy in stable patients post-HTx with T2DM and compared these with control patients for matched-pairs analysis. A total of 30 stable patients post-HTx with T2DM were included in the study. Fifteen patients (mean age 58.6 ± 6.0 years, mean time post-HTx 4.9 ± 5.3 years, twelve male and three female) were included in the vildagliptin group (VG) and 15 patients were included in the control group (CG) (mean age 61.2 ± 8.3 years, mean time post-HTx 7.2 ± 6.6 years, all male).
  
  
  RESULTS
  Mean glycated hemoglobin (HbA1c) in the VG was 7.4% ± 0.7% before versus 6.8% ± 0.8% after 8 months of vildagliptin therapy (P = 0.002 vs baseline). In the CG, HbA1c was 7.0% ± 0.7% versus 7.3% ± 1.2% at follow-up (P = 0.21). Additionally, there was a significant reduction in mean blood glucose in the VG, from 165.0 ± 18.8 mg/dL to 147.9 ± 22.7 mg/dL (P = 0.002 vs baseline), whereas mean blood glucose increased slightly in the CG from 154.7 ± 19.7 mg/dL to 162.6 ± 35.0 mg/dL (P = 0.21). No statistically significant changes in body weight (from 83.3 ± 10.8 kg to 82.0 ± 10.9 kg, P = 0.20), total cholesterol (1.5%, P = 0.68), or triglyceride levels (8.0%, P = 0.65) were seen in the VG. No significant changes in immunosuppressive drug levels or dosages were observed in either group.
  
  
  CONCLUSIONS
  Vildagliptin therapy significantly reduced HbA1c and mean blood glucose levels in post-HTx patients in this study with T2DM and did not have any negative effects on lipid profile or body weight. Thus, vildagliptin therapy presented an interesting therapeutic approach for this selected patient cohort.
authors: Department of Cardiology, University of Heidelberg, Heidelberg, Germany.
authors: Ibrahim
authors: I
authors: Gueler
authors: Susanne
authors: S
authors: Mueller
authors: Matthias
authors: M
authors: Helmschrott
authors: Christian U
authors: CU
authors: Oeing
authors: Christian
authors: C
authors: Erbel
authors: Lutz
authors: L
authors: Frankenstein
authors: Christian
authors: C
authors: Gleißner
authors: Arjang
authors: A
authors: Ruhparwar
authors: Philipp
authors: P
authors: Ehlermann
authors: Thomas J
authors: TJ
authors: Dengler
authors: Hugo A
authors: HA
authors: Katus
authors: Andreas O
authors: AO
authors: Doesch
mesh_terms: D000218:Adamantane / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077597:Vildagliptin
chemical_list: D000218:Adamantane; D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D007166:Immunosuppressive Agents; D008055:Lipids; D009570:Nitriles; D011759:Pyrrolidines; D000077597:Vildagliptin; C517652:hemoglobin A1c protein, human
keywords: glycated hemoglobin; immunosuppression; mean blood glucose
references: Horm Metab Res. 2006 Jun;38(6):423-8
references: 16823726
references: Diabetes Obes Metab. 2008 Nov;10(11):1047-56
references: 18284434
references: J Clin Pharmacol. 2008 Jan;48(1):85-95
references: 17986525
references: Horm Metab Res. 2008 Jun;40(6):427-30
references: 18401832
references: Curr Opin Pharmacol. 2004 Dec;4(6):589-96
references: 15525549
references: Diabetes Obes Metab. 2009 May;11(5):506-15
references: 19320662
references: JAMA. 2002 Jan 16;287(3):360-72
references: 11790216
references: J Clin Endocrinol Metab. 2005 Aug;90(8):4888-94
references: 15886245
references: Diabetes. 2004 Dec;53 Suppl 3:S197-204
references: 15561911
references: J Heart Lung Transplant. 2005 Jun;24(6):708-13
references: 15949731
references: Diabetes Res Clin Pract. 2007 Apr;76(1):132-8
references: 17223217
references: Vasc Health Risk Manag. 2008;4(6):1349-60
references: 19337548
references: Diabetes Obes Metab. 2007 Mar;9(2):175-85
references: 17300593
references: Diabetes Care. 2007 Apr;30(4):890-5
references: 17277036
references: J Clin Endocrinol Metab. 2008 Jan;93(1):103-9
references: 17925336
references: Curr Med Res Opin. 2007 Dec;23(12):2913-20
references: 17931461
references: Expert Opin Investig Drugs. 2006 Apr;15(4):431-42
references: 16548792
references: Diabetes Obes Metab. 2007 Mar;9(2):166-74
references: 17300592
references: Diabetologia. 2006 Sep;49(9):2049-57
references: 16816950
references: Transplant Proc. 2011 Jun;43(5):2113-5
references: 21693339
references: J Clin Endocrinol Metab. 2008 Feb;93(2):459-64
references: 18042650
references: J Clin Endocrinol Metab. 2009 Jan;94(1):81-8
references: 18957505
references: Int J Clin Pract Suppl. 2008 Mar;(159):15-23
references: 18269437
references: Diabetes Obes Metab. 2009 May;11 Suppl 2:9-17
references: 19385979
references: Can J Cardiol. 2009 Apr;25(4):e125-9
references: 19340357
references: Diabetologia. 2007 Jun;50(6):1148-55
references: 17387446
references: J Clin Endocrinol Metab. 2004 May;89(5):2078-84
references: 15126524
references: Diabetes Care. 2004 Dec;27(12):2874-80
references: 15562200
references: Vasc Health Risk Manag. 2010 Aug 09;6:541-8
references: 20730070
references: Kidney Int. 2006 Feb;69(3):588-95
references: 16395250
references: Diabetes Care. 2004 Jan;27(1):256-63
references: 14693998
references: Diabetes Obes Metab. 2005 Nov;7(6):692-8
references: 16219012
references: J Heart Lung Transplant. 1992 Sep-Oct;11(5):943-9
references: 1420243